Approved indications: Valganciclovir is approved to treat CMV retinitis in adults with AIDS and to prevent CMV disease in high‑risk kidney, heart, and kidney‑pancreas transplant recipients, including certain pediatric kidney (4 months–16 years) and heart (1 month–16 years) transplant patients.

• In CMV retinitis, it is used first at higher “induction” doses, then continued at a lower “maintenance” dose to keep the infection suppressed.
• In transplant patients at high risk for CMV, it is started within about 10 days after surgery and continued for several months to prevent CMV disease.

Off‑label uses (clinician‑directed): Clinicians may also use valganciclovir off‑label for preemptive treatment or prophylaxis of CMV infection after hematopoietic stem cell transplantation and, in some centers, for symptomatic congenital CMV disease, based on clinical studies showing good antiviral responses but with important toxicity risks.

Efficacy expectations:

• CMV levels in the blood often begin to fall within days to a couple of weeks after starting therapy, and eye lesions from CMV retinitis typically stabilize or improve over several weeks with continued treatment.
• For transplant prophylaxis, the benefit is mainly a reduced risk of CMV disease while the drug is taken; risk returns if prophylaxis is stopped in a still‑vulnerable patient.
• Oral valganciclovir provides drug exposure similar to IV ganciclovir and has comparable antiviral effectiveness, but both are more potent against CMV than older agents like acyclovir; newer CMV drugs may have less bone‑marrow toxicity but are used in different, specific settings.

Adults with normal kidney function: For CMV retinitis, a common regimen is 900 mg by mouth twice daily with food for 21 days (induction), then 900 mg once daily with food for maintenance; for CMV prevention after kidney, heart, or kidney‑pancreas transplant, 900 mg once daily with food is usually started within 10 days after surgery and continued for about 100–200 days as directed.

Children and adolescents: For CMV prevention after kidney or heart transplant, the dose is calculated using a formula that combines body‑surface area and kidney function (often written as 7 × BSA × creatinine clearance, up to a maximum of 900 mg once daily), and is given once daily with food using tablets or oral solution.

Kidney function and how to take it: Because the drug is cleared by the kidneys, doses must be reduced when kidney function is decreased, and dosing should not be used in the same way in patients on hemodialysis; tablets should be swallowed whole (never broken or crushed), and the oral solution is used when precise or smaller doses are needed.

Special instructions, missed doses, and overdose: Take valganciclovir at the same times each day and do not change the dose or stop suddenly unless your prescriber tells you to; if you miss a dose, take it as soon as you remember unless it is almost time for the next one (in which case skip the missed dose—do not double up), and if you or someone else may have taken too much, contact a poison control center or emergency medical services immediately.

Common side effects (often mild to moderate):

• Gastrointestinal issues such as diarrhea, nausea, vomiting, and stomach discomfort.
• General symptoms including fever, fatigue, headache, tremor, and trouble sleeping.
• Low blood counts (anemia, low white cells, low platelets) that may show up on blood tests and sometimes cause tiredness, easy bruising, or more frequent infections.

Serious or rare adverse effects needing immediate medical attention:

• Signs of infection (fever, chills, sore throat, cough, painful urination, or feeling very unwell), which can signal severe neutropenia.
• Unusual bleeding or bruising, tiny red spots on the skin, black or bloody stools, or blood in urine, which may indicate low platelets.
• Allergic reactions such as rash, swelling of the face or throat, trouble breathing, or severe dizziness.
• Kidney problems, including decreased urine, swelling of legs or face, sudden weight gain, confusion, or seizures.
• Severe confusion, hallucinations, seizures, or loss of consciousness.

Warnings and precautions:

• Blood and bone‑marrow effects: The drug can cause serious anemia, neutropenia, and thrombocytopenia; it is usually avoided if blood counts are already very low, and regular blood tests are required.
• Pregnancy and contraception: Animal and human data suggest risks of birth defects and pregnancy loss; effective contraception is recommended during treatment and for at least 30 days afterward for females and 90 days for males.
• Breastfeeding: Because of potential serious toxicity to a nursing infant, breastfeeding is generally not recommended while taking valganciclovir.
• Fertility and cancer risk: Valganciclovir (through ganciclovir) may reduce fertility in men and women and has mutagenic and carcinogenic potential based on animal studies, so long‑term risks should be discussed with the prescriber.
• Kidney and liver disease, older age: People with kidney impairment, dehydration, or older adults are at higher risk for toxicity and need dose adjustment and closer monitoring; liver problems also warrant caution.

Relative safety compared with other antivirals: Compared with many other antivirals (such as acyclovir or valacyclovir), valganciclovir carries a higher risk of bone‑marrow suppression, fertility effects, and potential carcinogenicity, so it is reserved for situations where strong CMV control is essential.

Monitoring and safety information: Patients typically need regular complete blood counts and kidney function tests; side effects should be reported promptly to a healthcare provider, and patients in the United States can also report adverse events and read safety updates through the FDA MedWatch program online or by phone.

Major drug interactions:

• Medicines that suppress the bone marrow (such as many chemotherapy drugs, zidovudine, azathioprine, or mycophenolate) can greatly increase the risk of severe anemia, neutropenia, and low platelets when combined with valganciclovir.
• Drugs that affect the kidneys (for example cyclosporine, tacrolimus, some high‑dose NSAIDs, or certain IV contrast dyes) may raise ganciclovir levels and increase the chance of kidney damage, so kidney function and drug levels may need closer monitoring.
• Probenecid, trimethoprim, and some older HIV medicines such as didanosine can interact pharmacokinetically with ganciclovir, potentially increasing side effects and requiring dose adjustments or alternative regimens.
• Combining valganciclovir or ganciclovir with imipenem‑cilastatin has been associated with seizures and is usually avoided unless no alternatives exist.

OTC medicines, supplements, alcohol, and food: Check with your clinician before taking new over‑the‑counter pain relievers (especially frequent or high‑dose NSAIDs), herbal products, or high‑dose supplements that might affect the kidneys or blood counts; valganciclovir should be taken with food to improve absorption, and while there is no specific alcohol prohibition, limiting alcohol is prudent because of potential added stress on the liver and bone marrow.

Conditions requiring extra caution:

• Existing low blood counts, prior bone‑marrow disease, or recent chemotherapy or radiation therapy.
• Kidney impairment, dehydration, or older age, all of which increase drug exposure and toxicity risk.
• History of seizures or significant neurologic disease, especially if taking other medicines that lower the seizure threshold.
• Pregnancy, plans for pregnancy, breastfeeding, or concerns about future fertility, given the drug’s fetal and reproductive risks.

Monitoring needs: Most patients require regular complete blood counts (with neutrophils, hemoglobin, and platelets) and kidney function tests before and during therapy; eye examinations are often used to follow CMV retinitis, and vital signs such as blood pressure are monitored as part of routine transplant or HIV care rather than specifically for the drug.

Q: How long will I need to take valganciclovir?
A: Treatment length varies by reason for use—CMV retinitis typically requires a few weeks of high‑dose therapy followed by many months of maintenance, while transplant CMV prevention often continues for about 3–6 months or longer, exactly as directed by your specialist.

Q: Can I crush or split valganciclovir tablets?
A: No; tablets should be swallowed whole because the drug can be harmful if the powder contacts skin or eyes, and if you cannot swallow tablets your clinician can prescribe the oral solution instead.

Q: What if I become pregnant while taking valganciclovir?
A: Contact your healthcare provider right away, because the medicine can potentially harm an unborn baby and you and your clinician will need to weigh benefits and risks and consider alternative options.

Q: Is it safe to breastfeed while on this medication?
A: Breastfeeding is generally not recommended during valganciclovir treatment because of the possibility of serious side effects in a nursing infant, so discuss feeding options with your healthcare team.

Q: Will I need regular blood tests while taking valganciclovir?
A: Yes, you will usually have blood counts and kidney function checked before starting and periodically during therapy to detect low blood cells or kidney problems early and adjust the dose if needed.

Storage: Store tablets at room temperature (about 68°F–77°F / 20°C–25°C) in the original bottle, and store the prepared oral solution in a refrigerator (36°F–46°F / 2°C–8°C) for no longer than 49 days; do not freeze and keep all forms out of the reach of children.

Handling: Do not break or crush tablets, and avoid getting powder or solution on your skin or in your eyes; if contact occurs, wash skin well with soap and water and rinse eyes with plenty of water.

Disposal: Do not keep medicine that is expired or no longer needed; follow local drug take‑back or pharmacist instructions for safe disposal and avoid putting leftover solution into household trash or wastewater when possible.